The surge in demand for Ozempic and similar GLP-1 drugs has left many people with diabetes struggling to access their medication, leading to serious health consequences. As weight loss claims overshadow the drug's intended purpose, individuals may overlook harmful side effects, risking disordered eating and weight cycling. The conversation highlights the broader implications of marketing and accessibility in healthcare, particularly for marginalized communities.
